Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Insulet's average EBITDA Per Share Growth Rate was 67.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 63.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 37.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Insulet was 262.50% per year. The lowest was -15.90% per year. And the median was 36.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Insulet 5-Year EBITDA Growth Rate Related Terms
PODD vs GMED, PEN, BRKR: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Insulet's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Insulet's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 37.60% mean?
Insulet (PODD) has a 5-Year EBITDA Growth Rate of 37.60% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Insulet and its competitors.
Is Insulet's 5-Year EBITDA Growth Rate too high?
Insulet's current 5-Year EBITDA Growth Rate is 37.60%. Overall, Insulet has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's 5-Year EBITDA Growth Rate compare to GMED and PEN?
Insulet's 5-Year EBITDA Growth Rate of 37.60% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Insulet and its competitors. Insulet's current 5-Year EBITDA Growth Rate is 37.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is $389.35, compared to a current price of $143.34 — trading 63.2% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 37.60%. Insulet's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Insulet (PODD), the current 5-Year EBITDA Growth Rate is 37.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insulet (PODD) Overvalued in 2026?
Based on GuruFocus' analysis, Insulet stock appears to be undervalued.
The current stock price of $143.34 is trading 63.2% below its estimated GF Value™ of $389.35.
GuruFocus considers Insulet to be Significantly Undervalued.
Key valuation signals for PODD:
5-Year EBITDA Growth Rate: 37.60%
GF Value™: $389.35 vs. price of $143.34 (63.2% below fair value)
No single metric tells the full story. See the PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
81GF Score
Get the complete analysis for PODD
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PODD has been successfully added to your 
